Dr. Sahn is the Vice President of Drug Development at 4E Therapeutics. He received his Ph.D. from North Carolina State University (Professor Daniel Comins) and conducted postdoctoral studies at The University of Texas at Austin (Professor Stephen Martin). He has over 15+ years of experience in synthetic-organic chemistry with a key focus on the design and synthesis of bioactive small molecules having medicinally-relevant activities. Research efforts have spanned the areas of medicinal chemistry, chemical biology, pharmacology, pharmacokinetics, and neurodegenerative disease biology. In his previous position as Research Scientist at The University of Texas at Austin, Dr. Sahn directs a multidisciplinary team with collaborators across the country to study transmembrane protein 97 (TMEM97). These works recently led to the cloning of TMEM97, as well as the discovery that TMEM97 is involved in a number of neurological conditions. Utilizing both in vitro- and animal disease models, Dr. Sahn and his team have identified a first-in-class clinical candidate for retinal degenerative conditions that functions through modulation of TMEM97. Sahn has supervised and mentored a number of students and postdocs, has co-authored 16 publications, is co-inventor on six patent applications, and is co-founder of NuvoNuro, Inc., an Austin TX-based biotech startup. Dr. Sahn and Dr. Price have been collaborating for the past 6 years.